Novavax, Inc. (LON:0A3S)

Market Cap	944.57M -17.8%
Revenue (ttm)	792.04M +20.3%
Net Income	254.24M
EPS	1.54
Shares Out	n/a
PE Ratio	3.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,654
Average Volume	178,166
Open	8.30
Previous Close	8.27
Day's Range	7.89 - 8.31
52-Week Range	5.02 - 10.65
Beta	2.58
RSI	46.10
Earnings Date	Feb 26, 2026

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 952
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A3S

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD